Leica Biosystems, part of Danaher, agreed to acquire Statlab Medical Products to expand Danaher’s diagnostics and anatomical pathology footprint. The deal strengthens access to a broader mix of instruments and consumables across workflow needs in pathology labs. Financial terms were not disclosed, but an RBC Capital Markets analyst estimated the acquisition value could exceed $1 billion. The move signals continued consolidation in pathology tooling as lifecycle management and consumables become central to margins and recurring revenue.